1-(4-溴苯基)环丙烷羧酰胺 | 847361-67-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-(4-溴苯基)环丙烷羧酰胺
• 英文名称: 1-(4-bromophenyl)cyclopropanecarboxamide
• 英文别名: 1-(4-bromophenyl)cyclopropane-1-carboxamide
• CAS: 847361-67-5
• 化学式: C₁₀H₁₀BrNO
• 分子量: 240.099
• InChiKey: WEBHXXBBDYMULJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(4-溴苯基)环丙烷羧酰胺 在 劳森试剂 、 trans-N,N'-dimethyl-1,2-cyclohexyldiamine 、 copper(l) iodide 、 sodium azide 、 sodium ascorbate 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 反应 21.0h， 生成 2-(1-(4-azidophenyl)cyclopropyl)-4-(pyridin-4-yl)thiazole
  参考文献：
  名称：

  Examining the Mechanism of Action of a Kinesin Inhibitor Using Stable Isotope Labeled Inhibitors for Cross-Linking (SILIC)

  摘要：

  It is difficult to determine a chemical inhibitor's binding site in multiprotein mixtures, particularly when high-resolution structural studies are not straightforward. Building upon previous research involving photo-cross-linking and the use of mixtures of stable isotopes, we report a method, Stable Isotope Labeled Inhibitors for Cross-linking (SILIC), for mapping a small molecule inhibitor's binding site in its target protein. In SILIC, structure-activity relationship data is used to design inhibitor analogues that incorporate a photo-cross-linking group along with either natural or 'heavy' stable isotopes. An equimolar mixture of these inhibitor analogues is cross-linked to the target protein to yield a robust signature for identifying inhibitor-modified peptide fragments in complex mass spectrometry data. As a proof of concept, we applied this approach to an ATP-competitive inhibitor of kinesin-5, a widely conserved motor protein required for cell division and an anticancer drug target. This analysis, along with mutagenesis studies, suggests that the inhibitor binds at an allosteric site in the motor protein.

  DOI：

  10.1021/ja204561q
• 作为产物：
  描述：

  1-(4-溴苯基)环丙甲酸 在 sodium sulfate 、 N,N'-羰基二咪唑 、 ammonium hydroxide 作用下， 以 四氢呋喃 为溶剂， 以70 %的产率得到1-(4-溴苯基)环丙烷羧酰胺
  参考文献：
  名称：

  电诱导霍夫曼重排合成环丙​​胺

  摘要：

  根据电诱导霍夫曼重排，公开了从相应的酰胺到环丙胺的实际途径。在恒电流条件下的未分隔电池中，一组环丙基酰胺很容易转化为相应的胺（17 个实例，23% 至 94% 产率）。该反应可以轻松获得多功能环丙胺，并且是对现有方法的补充。

  DOI：

  10.1055/a-2050-9368

文献信息

• [EN] CATHEPSIN CYSTEINE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE CATHEPSINE ET DE CYSTEINE PROTEASE
  申请人：MERCK FROSST CANADA INC

  公开号：WO2005019161A1

  公开（公告）日：2005-03-03

  This invention relates to a novel class of compounds, represented by the formula below, wherein the meanings of G, E, E, n, R1, R2, R3 et R4 are indicated therein, which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

  本发明涉及一类新颖的化合物，其由下述公式表示，其中G、E、E、n、R1、R2、R3和R4的含义如公式中所示，这些化合物是半胱氨酸蛋白酶抑制剂，包括但不限于组织蛋白酶K、L、S和B的抑制剂。这些化合物可用于治疗那些指示抑制骨吸收的疾病，例如骨质疏松症。
• [EN] CATHEPSIN INHIBITORS<br/>[FR] INHIBITEURS DE LA CATHEPSINE
  申请人：MERCK FROSST CANADA INC

  公开号：WO2005021487A1

  公开（公告）日：2005-03-10

  This invention relates to a novel class of compounds, represented by the formula (I) below, wherein the meanings of R1, R2, R3 and R4 are indicated therein, which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis, osteoarthritis and rheumatoid arthritis.

  这项发明涉及一类新型化合物，由下式（I）表示，其中R1、R2、R3和R4的含义已在其中指示，这些化合物是半胱氨酸蛋白酶抑制剂，包括但不限于对卡特普辛K、L、S和B的抑制剂。这些化合物对于治疗需要抑制骨吸收的疾病非常有用，如骨质疏松症、骨关节炎和类风湿性关节炎。
• [EN] PYRROLOPYRAZINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PYRROLOPYRAZINE KINASE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013030138A1

  公开（公告）日：2013-03-07

  The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

  本发明涉及式I的新型吡咯并吡嗪衍生物的使用，其中变量如本文所述定义，其抑制JAK和SYK，并可用于治疗自身免疫和炎症性疾病。
• [EN] CATHEPSIN CYSTEINE PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DES PROTEASES A CYSTEINE DU TYPE CATHEPSINE
  申请人：MERCK FROSST CANADA INC

  公开号：WO2005056529A1

  公开（公告）日：2005-06-23

  This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

  这项发明涉及一类新型化合物，它们是半胱氨酸蛋白酶抑制剂，包括但不限于对卡特普辛K、L、S和B的抑制剂。这些化合物对于治疗需要抑制骨吸收的疾病，如骨质疏松症，非常有用。
• [EN] CATHEPSIN CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF VARIOUS DISEASES<br/>[FR] INHIBITEURS DE LA CATHEPSINE CYSTÉINE PROTÉASE POUR TRAITER DES MALADIES VARIÉES
  申请人：MERCK FROSST CANADA LTD

  公开号：WO2010148488A1

  公开（公告）日：2010-12-29

  The present invention relates to compounds capable of inhibiting and/or decreasing the activity of one or more cathepsins, thereby treating and/or preventing various disease states associated with one or more cysteine proteases including, but not limited to, cathepsins and papain-like cysteine proteases. Disease states treated and/or prevented by the compounds of the invention include, but are not limited to, mammalian parasitic diseases in which the parasite utilizes a critical cysteine protease from the papain family. Examples of parasitic diseases to be treated or prevented by the compounds of the invention include, but are not limited to, toxoplasmosis, malaria, African trypanosomiasis, Chagas disease, leishmaniasis, coccidiosis, giardiosis, cryptosporidiosis or schistosomiasis.

  本发明涉及一种能够抑制和/或减少一种或多种半胱氨酸蛋白酶活性的化合物，从而治疗和/或预防与一种或多种半胱氨酸蛋白酶相关的各种疾病状态，包括但不限于cathepsins和木瓜蛋白酶样半胱氨酸蛋白酶。本发明的化合物治疗和/或预防的疾病状态包括但不限于寄生于哺乳动物的寄生病，其中寄生虫利用木瓜家族的关键半胱氨酸蛋白酶。本发明的化合物可用于治疗或预防的寄生病例包括但不限于弓形虫病、疟疾、非洲锥虫病、查加斯病、利什曼病、球虫病、贾第虫病、隐孢子虫病或血吸虫病。